The incretin effect describes the observation that oral glucose produces a stronger insulin response than intravenous glucose delivering the same blood-sugar load. The gut is not just absorbing nutrients; it is actively telling the pancreas what is happening. Two of the most important hormones in that message are GLP-1 and GIP.

That is why incretin biology sits inside the enteroinsular axis — the gut-to-pancreas communication network that links food intake to insulin release, appetite signaling, and metabolic regulation.

Incretin signaling is attractive because it is glucose-dependent. That means the pathway tends to amplify insulin release when glucose is elevated rather than driving insulin indiscriminately in every context. This is one reason incretin mimetics are discussed differently from insulin itself.

GLP-1 and GIP are related but not interchangeable. Dual and triple agonists exploit that difference by stacking receptor programs: one receptor profile can emphasize satiety and glycemic control, while another can add energy-expenditure or complementary metabolic effects.

GLP-1-focused compounds emphasize the classic incretin pathway. Dual agonists add GIP to change the receptor balance. Triple agonists add a glucagon component, which introduces a different metabolic dimension again. The result is not just a stronger version of GLP-1 signaling; it is a different receptor architecture altogether.

This is why metabolic researchers compare single, dual, and triple agonists as separate design philosophies rather than as a simple dose ladder.